Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Via Festa del Perdono 7, Milan 20122, Italy; IRCCS Istituto Ortopedico Galeazzi, U.O. Neurochirurgia Oncologica, Milan, Italy.
Unit of Nuclear Medicine, Humanitas Clinical and Research Center - IRCCS, Via Manzoni 56, Rozzano, Milan 20089, Italy. Electronic address: https://twitter.com/LopciEgesta.
Neurosurg Clin N Am. 2021 Jan;32(1):31-46. doi: 10.1016/j.nec.2020.08.003. Epub 2020 Nov 5.
Conventional magnetic resonance imaging (cMRI) has an established role as a crucial disease parameter in the multidisciplinary management of glioblastoma, guiding diagnosis, treatment planning, assessment, and follow-up. Yet, cMRI cannot provide adequate information regarding tissue heterogeneity and the infiltrative extent beyond the contrast enhancement. Advanced magnetic resonance imaging and PET and newer analytical methods are transforming images into data (radiomics) and providing noninvasive biomarkers of molecular features (radiogenomics), conveying enhanced information for improving decision making in surgery. This review analyzes the shift from image guidance to information guidance that is relevant for the surgical treatment of glioblastoma.
传统磁共振成像（cMRI）在胶质母细胞瘤的多学科综合管理中作为一个关键的疾病参数，对指导诊断、治疗计划、评估和随访具有重要作用。然而，cMRI 不能提供关于组织异质性和对比增强之外的浸润范围的充分信息。先进的磁共振成像、PET 和更新的分析方法正在将图像转化为数据（放射组学），并提供分子特征的非侵入性生物标志物（放射基因组学），为提高手术决策提供更丰富的信息。本文分析了从图像引导到信息引导的转变，这与胶质母细胞瘤的手术治疗有关。
